Abstract
Escalation of drug development costs, and low success rates have forced bio-pharmaceutical companies to focus on developing countries to set up a base. Growing aged population, escalating healthcare costs have forced Healthcare authorities around the world to favour cost-effective generic drugs over unaffordable Branded Biopharmaceuticals. This has opened vistas of opportunities for well established players like India, which is already established in the Chemical Generics market.
This Research Service explores key trends, Drivers, Restraints as well as Challenges faced by the evolving Indian Biogenerics industry through a study of prominent Biogeneric drugs manufactured in India and outlines strategies, based on the same.
View Cart
